Glenmark Pharmaceuticals’ Board of Directors has approved an interim dividend of ₹2.50 per equity share for the financial year 2025-26, totaling ₹705.50 million. The record date for dividend payment is October 3, 2025. Additionally, the Board has reconstituted its key committees, effective October 1, 2025, including the Stakeholders Relationship, Risk Management, and ESG Committees.
Interim Dividend Announcement
The Board has approved an interim dividend of ₹2.50 per equity share (face value of ₹1) for the financial year 2025-26. This distribution amounts to ₹705.50 million. The record date to determine eligibility for the dividend payout is Friday, October 3, 2025. Payments will be processed within 30 days of declaration.
Board Committee Revisions
Effective October 1, 2025, the company has reconstituted its key Board committees. These changes affect the composition of the Stakeholders Relationship Committee, the Risk Management Committee, and the ESG (Environmental, Social, and Governance) Committee.
Stakeholders Relationship Committee
The Stakeholders Relationship Committee will be chaired by Ms. Sona Saira Ramasastry, with Mrs. Cherylann Pinto and Ms. Patricia Andrews serving as members.
Risk Management Committee
The Risk Management Committee will be chaired by Mr. Dipankar Bhattacharjee, with members including Mr. Glenn Saldanha, Ms. Patricia Andrews, and Mr. Anurag Mantri.
ESG Committee
The ESG Committee will be chaired by Mr. Glenn Saldanha, and include Ms. Sona Saira Ramasastry, Mr. Pradeep Kumar Sinha, and Ms. Patricia Andrews as members.
Source: BSE
